HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

QYUNS-B

11.240

+0.2001.81%

Volume:102.40K

Turnover:1.13M

Market Cap:2.50B

PE:-6.85

High:11.300

Open:11.000

Low:10.760

Close:11.040

Loading ...

Overview Company News Filings

Qyuns Therapeutics Licenses Immunologic Disorder Drug to Caldera Therapeutics

MT Newswires Live

HK Movers | Biotech Stocks Jump With ImmuneOnco up 10%

Tiger Newspress

BRIEF-Qyuns Therapeutics Enters Exclusive License Agreement With Caldera Therapeutics

Qyuns Therapeutics Co Ltd - Caldera Therapeutics Granted Exclusive Rights to QX030n

THOMSON REUTERS

BRIEF-Qyuns Therapeutics Says Founder, Others Voluntarily Undertaken Not To Sell Any Shares Of Co

BRIEF-Qyuns Therapeutics To Subscribe For Wealth Management Products

Qyuns Therapeutics - to Subscribe for Wealth Management Products Offered by Pdb With Principal Amount of RMB60 Mln

THOMSON REUTERS

Qyuns Therapeutics Gets China Nod to Add Pediatric Plaque Psoriasis Indication to Drug

MT Newswires Live

Retail investors invested in Qyuns Therapeutics Co., Ltd. (HKG:2509) copped the brunt of last week's HK$155m market cap decline

Simply Wall St.

Qyuns Therapeutics' Clinical Study of Anti-Inflammatory Injection for Spinal Joints Shows Positive Results

MT Newswires Live

BRIEF-Qyuns Therapeutics Updates On Phase III Clinical Trial Of QX002N

Qyuns Therapeutics Co Ltd - Phase Iii Clinical Trial of QX002n for Ankylosing Spondylitis Reaches Primary Endpoint

THOMSON REUTERS

BRIEF-Qyuns Therapeutics Says Acceptance Of Marketing Authorisation Application & Supplemental Application For QX001S Injection

Qyuns Therapeutics - Acceptance of Marketing Authorisation Application and Supplemental Application for QX001s Injection for Crohn's Disease

THOMSON REUTERS

BRIEF-Qyuns Therapeutics Announces Subscription Of Wealth Management Products

Qyuns Therapeutics Co Ltd - Subscription of Wealth Management Products

THOMSON REUTERS

Qyuns Therapeutics Co., Ltd.'s (HKG:2509) last week's 20% decline must have disappointed individual investors who have a significant stake

Simply Wall St.

Qyuns Therapeutics' Plaque Psoriasis Drug Gets Registration Certificate from Chinese Regulator

MT Newswires Live

Qyuns Therapeutics - QX001s (Sailexin, Ustekinumab Injection) Drug Registration Certificate Approved and Issued by Nmpa

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/02509/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02509","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02509\",,,,,undefined,":{"symbol":"02509","market":"HK","secType":"STK","nameCN":"QYUNS-B","latestPrice":11.24,"timestamp":1746173305030,"preClose":11.04,"halted":0,"volume":102400,"delay":0,"floatShares":222000000,"shares":222000000,"eps":-1.6404512289682323,"marketStatus":"Closed","change":0.2,"latestTime":"05-02 16:08:25","open":11,"high":11.3,"low":10.76,"amount":1128992,"amplitude":0.048913,"askPrice":11.24,"askSize":10000,"bidPrice":11.14,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-1.6404512289682323,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1746495000000},"marketStatusCode":5,"adr":0,"listingDate":1710864000000,"exchange":"SEHK","adjPreClose":11.04,"openAndCloseTimeList":[[1746149400000,1746158400000],[1746162000000,1746172800000]],"volumeRatio":0.448101,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02509\",,,,,undefined,":{"symbol":"02509","floatShares":222000000,"roa":"-24.04%","roe":"-133.98%","lyrEps":-1.640451,"volumeRatio":0.448101,"shares":222000000,"dividePrice":0,"high":11.3,"amplitude":0.048913,"preClose":11.04,"low":10.76,"week52Low":5.95,"pbRate":"10.16","psRate":"14.65","week52High":30.95,"institutionHeld":0,"latestPrice":11.24,"committee":-0.960784,"eps":-1.6404512289682323,"divideRate":0,"volume":102400,"delay":0,"ttmEps":-1.6404512289682323,"open":11,"prevYearClose":7.38,"prevWeekClose":10.96,"prevMonthClose":11.04,"prevQuarterClose":8.99,"fiveDayClose":10.58,"twentyDayClose":8.99,"sixtyDayClose":9.18},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02509\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529462340","title":"Qyuns Therapeutics Licenses Immunologic Disorder Drug to Caldera Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2529462340","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529462340?lang=en_us&edition=fundamental","pubTime":"2025-04-24 15:08","pubTimestamp":1745478530,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics  has granted Caldera Therapeutics an exclusive right to develop and commercialize QX030N globally under an out-license agreement, a Thursday Hong Kong bourse filing said.The biotechnology company will receive a one-time upfront payment of $10 million under the contract, as well as around 24.88% equity interest in Caldera Therapeutics.The firm may also receive additional milestone payments of up to $545 million and tiered royalties.QX030N is a long-acting bispecific antibody in the pre-clinical stage for the treatment of immunologic disorders.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4007","BK1161","LENZ","02509"],"gpt_icon":0},{"id":"1104696869","title":"HK Movers | Biotech Stocks Jump With ImmuneOnco up 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1104696869","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104696869?lang=en_us&edition=fundamental","pubTime":"2025-04-24 09:49","pubTimestamp":1745459345,"startTime":"0","endTime":"0","summary":"Biotech stocks surged in Hong Kong, with ImmuneOnco up 10%, RemeGen up 9%, Akeso and QYUNS up 6%, Lepu Biopharma up 5%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157","09926","01541","02509","09995"],"gpt_icon":0},{"id":"2529566730","title":"BRIEF-Qyuns Therapeutics Enters Exclusive License Agreement With Caldera Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2529566730","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529566730?lang=en_us&edition=fundamental","pubTime":"2025-04-24 06:36","pubTimestamp":1745447819,"startTime":"0","endTime":"0","summary":"BRIEF-Qyuns Therapeutics Enters Exclusive License Agreement With Caldera TherapeuticsApril 24 (Reuters) - Qyuns Therapeutics Co Ltd 2509.HK:ENTERS EXCLUSIVE LICENSE AGREEMENT WITH CALDERA THERAPEUTICS","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nFWN3R11AX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2529664503","title":"Qyuns Therapeutics Co Ltd - Caldera Therapeutics Granted Exclusive Rights to QX030n","url":"https://stock-news.laohu8.com/highlight/detail?id=2529664503","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529664503?lang=en_us&edition=fundamental","pubTime":"2025-04-24 06:03","pubTimestamp":1745445826,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nFWN3R11AX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2520746137","title":"BRIEF-Qyuns Therapeutics Says Founder, Others Voluntarily Undertaken Not To Sell Any Shares Of Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2520746137","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520746137?lang=en_us&edition=fundamental","pubTime":"2025-03-19 22:53","pubTimestamp":1742396039,"startTime":"0","endTime":"0","summary":"BRIEF-Qyuns Therapeutics Says Founder, Others Voluntarily Undertaken Not To Sell Any Shares Of CoMarch 19  - Qyuns Therapeutics Co Ltd 2509.HK:FOUNDER & CONTROLLING SHAREHOLDER VOLUNTARILY UNDERTAKEN NOT TO SELL ANY SHARES OF COFurther company coverage: 2509.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nFWN3Q20J4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"BRIEF-Qyuns Therapeutics Says Founder, Others Voluntarily Undertaken Not To Sell Any Shares Of Co","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2517434399","title":"BRIEF-Qyuns Therapeutics To Subscribe For Wealth Management Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2517434399","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517434399?lang=en_us&edition=fundamental","pubTime":"2025-03-07 23:11","pubTimestamp":1741360296,"startTime":"0","endTime":"0","summary":"BRIEF-Qyuns Therapeutics To Subscribe For Wealth Management ProductsMarch 7  - Qyuns Therapeutics Co Ltd 2509.HK:TO SUBSCRIBE FOR WEALTH MANAGEMENT PRODUCTS OFFERED BY PDB WITH PRINCIPAL AMOUNT OF RMB60 MILLIONTO SUBSCRIBE FOR WEALTH MANAGEMENT PRODUCTS OFFERED BY PDB WITH A PRINCIPAL AMOUNT OF RMB80 MILLIONFurther company coverage: 2509.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nFWN3PQ0F6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2517486245","title":"Qyuns Therapeutics  - to Subscribe for Wealth Management Products Offered by Pdb With Principal Amount of RMB60 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2517486245","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517486245?lang=en_us&edition=fundamental","pubTime":"2025-03-07 19:38","pubTimestamp":1741347502,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nFWN3PQ0F6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2516612571","title":"Qyuns Therapeutics Gets China Nod to Add Pediatric Plaque Psoriasis Indication to Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2516612571","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516612571?lang=en_us&edition=fundamental","pubTime":"2025-03-04 13:56","pubTimestamp":1741067813,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics  has received approval from China's National Medical Products Administration to add a new indication of pediatric plaque psoriasis to its product QX001S, a Monday filing with the Hong Kong bourse stated.The new indication is for children and adolescents aged 6 years and above with moderate-to-severe plaque psoriasis and an inadequate response to systemic therapies or phototherapy.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02509","BK4139","BK1161","LENZ"],"gpt_icon":0},{"id":"2516644888","title":"Retail investors invested in Qyuns Therapeutics Co., Ltd. (HKG:2509) copped the brunt of last week's HK$155m market cap decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2516644888","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516644888?lang=en_us&edition=fundamental","pubTime":"2025-03-04 07:27","pubTimestamp":1741044461,"startTime":"0","endTime":"0","summary":"Key Insights Qyuns Therapeutics' significant retail investors ownership suggests that the key decisions are influenced...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2509/qyuns-therapeutics-shares/news/retail-investors-invested-in-qyuns-therapeutics-co-ltd-hkg25","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","BK4139","LENZ","02509"],"gpt_icon":0},{"id":"2513725556","title":"Qyuns Therapeutics' Clinical Study of Anti-Inflammatory Injection for Spinal Joints Shows Positive Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2513725556","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513725556?lang=en_us&edition=fundamental","pubTime":"2025-02-24 20:45","pubTimestamp":1740401112,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics'  phase 3 clinical study of its QX002N injection reached its primary endpoint showing better efficacy, safety, and tolerance in patients with moderate-to-severe active ankylosing spondylitis, a Monday bourse filing said.The study showed the injection to have much higher efficacy than its market counterparts while its safety study revealed injection's treatment-emergent adverse events in grades 1 and 2.The drug's incidence of adverse event rating was comparable to that of marketed drugs in the same class, with no new safety signals identified, according to the filing.QX002N is a high-affinity monoclonal antibody and targets the IL-17A which is a key player in the pathological mechanism of various autoimmune diseases.The injection is for the treatment of the chronic progressive inflammatory disease of the spinal joints, Ankylosing Spondylitis.The disease causes inflammation of the spinal joints, resulting in reduced flexibility of the joints and stiffness in the spine ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","02509","LENZ","BK1161"],"gpt_icon":0},{"id":"2513744325","title":"BRIEF-Qyuns Therapeutics Updates On Phase III Clinical Trial Of QX002N","url":"https://stock-news.laohu8.com/highlight/detail?id=2513744325","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513744325?lang=en_us&edition=fundamental","pubTime":"2025-02-24 19:18","pubTimestamp":1740395924,"startTime":"0","endTime":"0","summary":"BRIEF-Qyuns Therapeutics Updates On Phase III Clinical Trial Of QX002NFeb 24 (Reuters) - Qyuns Therapeutics Co Ltd 2509.HK:PHASE III CLINICAL TRIAL OF QX002N FOR ANKYLOSING SPONDYLITIS REACHES PRIMARY ENDPOINTFurther company coverage: 2509.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nFWN3PF0YU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2513746158","title":"Qyuns Therapeutics Co Ltd - Phase Iii Clinical Trial of QX002n for Ankylosing Spondylitis Reaches Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2513746158","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513746158?lang=en_us&edition=fundamental","pubTime":"2025-02-24 18:31","pubTimestamp":1740393066,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nFWN3PF0YU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2510092013","title":"BRIEF-Qyuns Therapeutics Says Acceptance Of Marketing Authorisation Application & Supplemental Application For QX001S Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2510092013","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510092013?lang=en_us&edition=fundamental","pubTime":"2025-02-12 23:54","pubTimestamp":1739375660,"startTime":"0","endTime":"0","summary":"BRIEF-Qyuns Therapeutics Says Acceptance Of Marketing Authorisation Application & Supplemental Application For QX001S InjectionFeb 12  - Qyuns Therapeutics Co Ltd 2509.HK:ACCEPTANCE OF MARKETING AUTHORISATION APPLICATION AND SUPPLEMENTAL APPLICATION FOR QX001S INJECTION FOR CROHN'S DISEASEFurther company coverage: 2509.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250212:nFWN3P318N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2510277293","title":"Qyuns Therapeutics - Acceptance of Marketing Authorisation Application and Supplemental Application for QX001s Injection for Crohn's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2510277293","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510277293?lang=en_us&edition=fundamental","pubTime":"2025-02-12 19:31","pubTimestamp":1739359861,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250212:nFWN3P318N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2485797230","title":"BRIEF-Qyuns Therapeutics Announces Subscription Of Wealth Management Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2485797230","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485797230?lang=en_us&edition=fundamental","pubTime":"2024-11-22 18:36","pubTimestamp":1732271777,"startTime":"0","endTime":"0","summary":"BRIEF-Qyuns Therapeutics Announces Subscription Of Wealth Management ProductsNov 22 (Reuters) - Qyuns Therapeutics Co Ltd 2509.HK:SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTSTO SUBSCRIBE FOR SEPARATE WE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nFWN3MT0M8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2485201235","title":"Qyuns Therapeutics Co Ltd -  Subscription of Wealth Management Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2485201235","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485201235?lang=en_us&edition=fundamental","pubTime":"2024-11-22 16:46","pubTimestamp":1732265205,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nFWN3MT0M8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2483256512","title":"Qyuns Therapeutics Co., Ltd.'s (HKG:2509) last week's 20% decline must have disappointed individual investors who have a significant stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2483256512","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483256512?lang=en_us&edition=fundamental","pubTime":"2024-11-16 06:56","pubTimestamp":1731711387,"startTime":"0","endTime":"0","summary":"Key Insights The considerable ownership by individual investors in Qyuns Therapeutics indicates that they collectively...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2509/qyuns-therapeutics-shares/news/qyuns-therapeutics-co-ltds-hkg2509-last-weeks-20-decline-mus","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02509","BK1161","BK4139","LENZ"],"gpt_icon":0},{"id":"2481575945","title":"Qyuns Therapeutics' Plaque Psoriasis Drug Gets Registration Certificate from Chinese Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=2481575945","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481575945?lang=en_us&edition=fundamental","pubTime":"2024-11-05 18:48","pubTimestamp":1730803681,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics  affiliate Hangzhou Zhongmei Huadong Pharmaceutical has received a drug registration certificate for the ustekinumab injection approved by China's National Medical Products Administration, a Tuesday bourse filing said.The drug has been approved for the treatment of moderate-to-severe plaque psoriasis in adults.The ustekinumab injection was initially developed independently by Qyuns Therapeutics. The company later reached a collaboration agreement with Hangzhou Zhongmei Huadong Pharmaceutical to jointly advance its phase III clinical trial related to the drug.Shares of the biotechnology company closed nearly 2% higher on Tuesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","LENZ","02509","BK4139"],"gpt_icon":0},{"id":"2481522816","title":"Qyuns Therapeutics - QX001s (Sailexin, Ustekinumab Injection) Drug Registration Certificate Approved and Issued by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2481522816","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481522816?lang=en_us&edition=fundamental","pubTime":"2024-11-05 17:31","pubTimestamp":1730799119,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241105:nFWN3MC0SA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02509","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":19,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02509\",params:#limit:5,,,undefined,":[{"date":"2025-03-28","symbol":"02509","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1743125400000,"name":null,"time":"Post Market","dateTimestamp":1743091200000,"actualEps":null},{"date":"2024-08-15","symbol":"02509","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1723685400000,"name":null,"time":"","dateTimestamp":1723651200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02509\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02509\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02509\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02509","date":"2025-04-30","current":-6.845842,"percent":0.538745,"low":-14.747072,"twenty":-10.778854,"median":-7.826785,"eighty":-4.236326,"high":-3.10587,"avg":-7.570302,"sd":3.036514,"marketCap":2451670464},"quantilePoints":[{"date":"2024-03-22","current":-9.005941,"twenty":-9.920087,"median":-9.005941,"eighty":-8.797979,"marketCap":4652400020},{"date":"2024-03-28","current":-9.367246,"twenty":-9.484937,"median":-9.005941,"eighty":-8.416995,"marketCap":4821843660},{"date":"2024-04-05","current":-8.872714,"twenty":-9.396669,"median":-8.977885,"eighty":-8.598751,"marketCap":4565907160},{"date":"2024-04-12","current":-9.165919,"twenty":-9.386227,"median":-9.126184,"eighty":-8.830039,"marketCap":4719469060},{"date":"2024-04-19","current":-9.074252,"twenty":-9.304842,"median":-9.125412,"eighty":-8.934406,"marketCap":4668281760},{"date":"2024-04-26","current":-9.882424,"twenty":-9.513374,"median":-9.232059,"eighty":-8.994719,"marketCap":5077780160},{"date":"2024-05-03","current":-10.208268,"twenty":-9.517937,"median":-9.234052,"eighty":-9.046928,"marketCap":5241579520},{"date":"2024-05-10","current":-10.950727,"twenty":-10.058378,"median":-9.328243,"eighty":-9.081967,"marketCap":6018140360},{"date":"2024-05-17","current":-11.513141,"twenty":-10.522167,"median":-9.424295,"eighty":-9.09098,"marketCap":6317937020},{"date":"2024-05-24","current":-11.397533,"twenty":-11.287555,"median":-9.513128,"eighty":-9.098359,"marketCap":6240211960},{"date":"2024-05-31","current":-10.960491,"twenty":-11.380385,"median":-9.702863,"eighty":-9.110289,"marketCap":6007036780},{"date":"2024-06-07","current":-9.736726,"twenty":-11.329803,"median":-9.882424,"eighty":-9.125257,"marketCap":5329718400},{"date":"2024-06-14","current":-9.786262,"twenty":-11.239813,"median":-9.736726,"eighty":-9.134131,"marketCap":5351925560},{"date":"2024-06-21","current":-11.51586,"twenty":-11.394726,"median":-9.834343,"eighty":-9.179147,"marketCap":6284626280},{"date":"2024-06-28","current":-7.449742,"twenty":-11.394726,"median":-9.882424,"eighty":-9.134131,"marketCap":4063910280},{"date":"2024-07-05","current":-8.013266,"twenty":-11.3835,"median":-9.736726,"eighty":-9.096784,"marketCap":4370369088},{"date":"2024-07-12","current":-8.782148,"twenty":-11.375713,"median":-9.612459,"eighty":-8.973485,"marketCap":4796746560},{"date":"2024-07-19","current":-8.033889,"twenty":-11.260937,"median":-9.536435,"eighty":-8.759388,"marketCap":4388134816},{"date":"2024-07-26","current":-8.627957,"twenty":-11.24224,"median":-9.513744,"eighty":-8.627957,"marketCap":4730125080},{"date":"2024-08-02","current":-9.119354,"twenty":-11.155317,"median":-9.51436,"eighty":-8.659337,"marketCap":4996611000},{"date":"2024-08-09","current":-9.602516,"twenty":-11.096166,"median":-9.502501,"eighty":-8.759388,"marketCap":5296407660},{"date":"2024-08-16","current":-9.659156,"twenty":-11.082764,"median":-9.523303,"eighty":-8.782148,"marketCap":5329718400},{"date":"2024-08-23","current":-11.457751,"twenty":-11.24224,"median":-9.560506,"eighty":-8.785621,"marketCap":5274200500},{"date":"2024-08-30","current":-11.261539,"twenty":-11.260937,"median":-9.602516,"eighty":-8.853804,"marketCap":5218682600},{"date":"2024-09-06","current":-12.381731,"twenty":-11.301814,"median":-9.616314,"eighty":-8.872714,"marketCap":5740550860},{"date":"2024-09-13","current":-12.966504,"twenty":-11.41285,"median":-9.666597,"eighty":-8.919616,"marketCap":5995933200},{"date":"2024-09-20","current":-13.175636,"twenty":-11.495182,"median":-9.727036,"eighty":-8.943786,"marketCap":6129176160},{"date":"2024-09-27","current":-11.412309,"twenty":-11.503472,"median":-9.834343,"eighty":-8.968754,"marketCap":5340821980},{"date":"2024-10-04","current":-10.630177,"twenty":-11.500266,"median":-9.955419,"eighty":-8.992959,"marketCap":4952196680},{"date":"2024-10-10","current":-9.640046,"twenty":-11.496891,"median":-9.984689,"eighty":-9.012278,"marketCap":4463639160},{"date":"2024-10-18","current":-7.823087,"twenty":-11.483911,"median":-9.882424,"eighty":-8.891475,"marketCap":3602001352},{"date":"2024-10-25","current":-6.637022,"twenty":-11.464072,"median":-9.731881,"eighty":-8.768492,"marketCap":3055705216},{"date":"2024-11-01","current":-6.266219,"twenty":-11.439791,"median":-9.666597,"eighty":-8.552796,"marketCap":2886930800},{"date":"2024-11-08","current":-6.11978,"twenty":-11.412634,"median":-9.628889,"eighty":-8.354641,"marketCap":2798102160},{"date":"2024-11-15","current":-4.903744,"twenty":-11.406399,"median":-9.610023,"eighty":-8.146037,"marketCap":2225157432},{"date":"2024-11-22","current":-4.446271,"twenty":-11.39192,"median":-9.574881,"eighty":-7.917147,"marketCap":2016410128},{"date":"2024-11-29","current":-5.262129,"twenty":-11.380385,"median":-9.536435,"eighty":-7.700796,"marketCap":2385048984},{"date":"2024-12-06","current":-5.795133,"twenty":-11.346153,"median":-9.513744,"eighty":-7.24659,"marketCap":2620444880},{"date":"2024-12-13","current":-4.23234,"twenty":-11.292835,"median":-9.462151,"eighty":-6.614509,"marketCap":1912036476},{"date":"2024-12-20","current":-3.65763,"twenty":-11.272236,"median":-9.353096,"eighty":-6.423955,"marketCap":1643329840},{"date":"2024-12-27","current":-3.704989,"twenty":-11.261539,"median":-9.289241,"eighty":-6.377951,"marketCap":1663316284},{"date":"2025-01-03","current":-3.459219,"twenty":-11.261057,"median":-9.234052,"eighty":-6.353973,"marketCap":1554501200},{"date":"2025-01-10","current":-3.422771,"twenty":-11.250301,"median":-9.146052,"eighty":-6.232964,"marketCap":1532294040},{"date":"2025-01-17","current":-3.325837,"twenty":-11.24332,"median":-9.119354,"eighty":-5.607796,"marketCap":1490100436},{"date":"2025-01-24","current":-3.940539,"twenty":-11.188065,"median":-9.092192,"eighty":-5.378133,"marketCap":1776572800},{"date":"2025-01-28","current":-4.706176,"twenty":-11.17068,"median":-9.087355,"eighty":-5.266211,"marketCap":2131887360},{"date":"2025-02-07","current":-3.301677,"twenty":-11.154739,"median":-9.066381,"eighty":-4.958001,"marketCap":1487879720},{"date":"2025-02-14","current":-3.418254,"twenty":-11.143754,"median":-8.989713,"eighty":-4.539173,"marketCap":1536735472},{"date":"2025-02-21","current":-3.43891,"twenty":-11.106485,"median":-8.919616,"eighty":-4.354459,"marketCap":1554501200},{"date":"2025-02-28","current":-3.351703,"twenty":-11.093486,"median":-8.819713,"eighty":-4.122814,"marketCap":1510086880},{"date":"2025-03-07","current":-3.387392,"twenty":-11.071174,"median":-8.759388,"eighty":-3.975573,"marketCap":1532294040},{"date":"2025-03-14","current":-5.398225,"twenty":-11.023325,"median":-8.622598,"eighty":-3.975573,"marketCap":2442787600},{"date":"2025-03-21","current":-4.408646,"twenty":-11.005989,"median":-8.475358,"eighty":-3.996365,"marketCap":1994202968},{"date":"2025-03-28","current":-4.427424,"twenty":-10.958538,"median":-8.354936,"eighty":-4.069456,"marketCap":1998644400},{"date":"2025-04-03","current":-5.532239,"twenty":-10.950727,"median":-8.251895,"eighty":-4.071454,"marketCap":1987540820},{"date":"2025-04-11","current":-5.176788,"twenty":-10.949179,"median":-8.134698,"eighty":-4.113712,"marketCap":1843194280},{"date":"2025-04-17","current":-5.605956,"twenty":-10.931954,"median":-8.013266,"eighty":-4.15012,"marketCap":1998644400},{"date":"2025-04-25","current":-6.813611,"twenty":-10.860673,"median":-7.855635,"eighty":-4.203093,"marketCap":2433904736},{"date":"2025-04-30","current":-6.845842,"twenty":-10.778854,"median":-7.826785,"eighty":-4.236326,"marketCap":2451670464}],"updateTime":1746159724612}}}